← All indications
Purpura
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS).
Subtype terms (5)
More specific conditions that are subtypes of Purpura in the MeSH hierarchy.
- IgA Vasculitis
24 drugs (21 approved, 3 experimental)
- Purpura Fulminans
- Purpura, Hyperglobulinemic
- Purpura, Thrombocytopenic
10 drugs (9 approved, 1 experimental)
- Waterhouse-Friderichsen Syndrome
Drugs by status
Phase 4 trials (8)
Phase 3 trials (14)
Phase 2 trials (25)
Organizations
Organization Involved with Phase 4 Indications (23)
- CSL Behring
- Amgen
- GlaxoSmithKline
- Huazhong University of Science and Technology
- Anhui Medical University
- Mahidol University
- Norwegian University of Science and Technology
- Shanxi Medical University
- The Center for Clinical and Cosmetic Research
- University of Oslo
- University of Oulu
- Xinjiang Medical University
- Assiut University
- Zhejiang Chinese Medical University
- Shandong University
- Tsinghua University
- University of Vienna
- Jiao Tong University
- Medical University of Vienna
- Samodzielny Publiczny Szpital
- Shandong University of Traditional Chinese Medicine
- China Medical University
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (90)
- Ablynx
- Eisai
- Shire
- Bio Products Laboratory
- Roche
- CSL
- Genentech
- Octapharma
- Grifols
- Sanofi
- Biogen
- Novartis
- Anthera Pharmaceuticals
- Baxalta
- Bayer
- Hamilton Health Sciences Corporation
- Hengrui Therapeutics, Inc.
- Kissei Pharmaceuticals
- Kyowa Hakko Kirin
- Rigel Pharmaceuticals
- Sunshine Lake Pharma Co., Ltd.
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Pittsburgh
- Pakistan Army
- Case Western Reserve University
- Cornell University
- Harvard University
- Duke University
- +60 more
Organization Involved with Phase 2 Indications (57)
- Galderma
- Swedish Orphan Biovitrum
- Bristol-Myers Squibb
- Immunomedics
- AstraZeneca
- Archemix Corp.
- PhytoHealth Corporation
- Symphogen A/S
- Iltoo Pharma
- Principia Biopharma, Inc.
- Fondazione Progetto Ematologia
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Aarhus University
- Changhua Christian Hospital
- University of London
- China Academy of Chinese Medical Sciences
- Etablissement Français du Sang
- Glaser Pediatric Research Network
- Hematology and Oncology Specialists
- Henan University of Traditional Chinese Medicine
- Kaohsiung Medical University
- Katholieke Universiteit Leuven
- Kunming Medical University
- Multispecialty Aesthetic Clinical Research Organization
- Nanjing Medical University
- National Cheng Kung University
- Southwest Oncology Group
- University of Michigan
- +27 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (7)